Evidence map›Paper›PMID 31615710›Full record

ArticleEuropean urology2020

Clinical Acumen Versus Androgen Receptor Variant 7 Circulating Tumor Cells in Decision-Making for Men with Advanced Prostate Cancer.

Bruce Montgomery, Stephen Plymate

Abstract readEditorialComment
PubMed Publisher
In one paragraph

Article in European urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 80% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Bruce MontgomeryVA Puget Sound, Seattle, WA, USA; University of Washington, Seattle, WA, USA. Electronic address: rbmontgo@uw.edu.
Stephen PlymateVA Puget Sound, Seattle, WA, USA; University of Washington, Seattle, WA, USA.
University of Washington · USVA Puget Sound Health Care System · US

Funding

TRANSCRIPTOME AND PROTEOME STRATIFICATION OF PROSTATE ADENOCARCINOMA PHENOTYPESP50CA097186 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI John Kyung Lee · 2002 to 2026
$58.1M
Mechanisms for the Transition to Castrate Resistant Prostate CancerI01BX000585 · VA · VA PUGET SOUND HEALTHCARE SYSTEM · PI PLYMATE, STEPHEN R. · 2009 to 2013
–
Targeting the Metabolome in Androgen Receptor-driven Castration-resistant Prostate CancerI01BX003324 · VA · VA PUGET SOUND HEALTHCARE SYSTEM · PI PLYMATE, STEPHEN R. · 2016 to 2024
–
BLRD VA I01 BX000585BLRD VA I01 BX003324NCI NIH HHS P50 CA097186
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Neoplastic Cells, CirculatingProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantAndrogen AntagonistsBiomarkersHumansMaleReceptors, AndrogenAndrogen AntagonistsBiomarkersReceptors, Androgen

Identifiers

PMID31615710
OpenAlexW2979540284

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.